Sawai Group Holdings Co., Ltd.

4887

JP3323040000

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
5,957 ^JPY	+0.17%		+0.39%	+14.36%

Apr. 03	Sawai Group Finalizes Sale of US Subsidiary	MT
Apr. 01	Bora Pharmaceuticals Co., LTD. completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd..	CI

Neurolief Ltd. announced that it has received funding from Sawai Group Holdings Co., Ltd.

December 27, 2023

Neurolief Ltd. announced that it has raised funds in an equity round of funding on December 28, 2023. The transaction included participation from returning investor, Sawai Group Holdings Co., Ltd.

Latest news about Sawai Group Holdings Co., Ltd.

Sawai Group Finalizes Sale of US Subsidiary	Apr. 03	MT
Bora Pharmaceuticals Co., LTD. completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd..	Mar. 31	CI
Jefferies Adjusts Sawai Group’s Price Target to 5,000 Yen From 5,200 Yen, Keeps at Hold	Mar. 06	MT
Sawai Group Holdings Co., Ltd. Provides Year End Dividend Guidance for the Year Ending March 31, 2024	Feb. 13	CI
Sawai Group Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	Feb. 13	CI
Bora Pharmaceuticals Co., LTD. agreed to acquire Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. for approximately $210 million.	Jan. 15	CI
Neurolief Ltd. announced that it has received funding from Sawai Group Holdings Co., Ltd.	Dec. 27	CI
Jefferies Adjusts Sawai’s Price Target to 4,500 Yen From 3,500 Yen, Keeps at Hold	Nov. 22	MT
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	Nov. 10	CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	Nov. 10	CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2024	23-08-09	CI
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for Period Ending September 2023 and Year Ending March 2024	23-08-09	CI
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half Year Ending September 2023 and Fiscal Year Ending March 31, 2024	23-05-11	CI
Sawai Group Holdings Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024	23-05-11	CI
Sawai Group Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-10	CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2023	23-02-12	CI
Sawai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	23-02-12	CI
Sawai Group Holdings Co., Ltd. Announces Dividend for the Second Quarter Ending September 30, 2022, Payable on December 2, 2022; Provides Dividend Guidance for the Year Ending March 31, 2023	22-11-08	CI
Sawai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	22-11-08	CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2023	22-08-10	CI
Sawai Group Holdings Co., Ltd. Provides Earnings Guidance for Period Ending September 2022 and Year Ending March 2023	22-08-10	CI
Japan Index Trades Steadily in Red; Round One Shares Gain 9% as May Sales Exceed Pre-Pandemic Level	22-06-10	MT
Chugai Appeals Tokyo Court's Dismissal of Patent Infringement Lawsuit Against Sawai, Nichi-iko Pharmaceutical	22-06-10	MT
Court Denies Chugai's Claim in Lawsuit Against Sawai, Nichi-iko	22-05-30	MT
Transcript : Sawai Group Holdings Co., Ltd., 2022 Earnings Call, May 12, 2022	22-05-12

Chart Sawai Group Holdings Co., Ltd.

Duration

Period

More charts

Sawai Group Holdings Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of medical and over-the-counter drugs. The Company operates in two segments. The Japan segment is engaged in medical and healthcare-related businesses such as manufacture and sale of pharmaceuticals and medical devices, as well as various related businesses. The America segment is engaged in the sale of manufactured pharmaceutical products to wholesale stores in America. The company is also engaged in the research and development of pharmaceutical products.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Sawai Group Holdings Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5,957 JPY

Average target price

6,780 JPY

Spread / Average Target

+13.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SAWAI GROUP HOLDINGS CO., LTD.	+14.36%	1.66B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Sawai Group Holdings Co., Ltd.

Equities

4887

JP3323040000

Pharmaceuticals

Neurolief Ltd. announced that it has received funding from Sawai Group Holdings Co., Ltd.

Latest news about Sawai Group Holdings Co., Ltd.

Chart Sawai Group Holdings Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Sawai Group Holdings Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals